Today: 29 June 2026
NAB share price drops again as trade jitters bite — what National Australia Bank investors watch next
5 February 2026
1 min read

NAB share price holds near A$44 after RBA hike as traders eye Feb 18 update

SYDNEY, Feb 5, 2026, 17:09 AEDT — After-hours update.

  • NAB shares rose slightly post-close, keeping attention on banks following the RBA’s unexpected rate increase.
  • Australia’s major four banks have signaled they will raise variable mortgage rates starting mid-February.
  • Upcoming catalysts: RBA minutes drop Feb 17, followed by NAB’s Q1 trading update on Feb 18.

Shares of National Australia Bank Limited (NAB.AX) ended Thursday’s session up 0.27%, closing at A$44.05.

The stock now serves as a barometer for investors’ expectations on Australian rates. While higher rates can boost bank profits, they also increase the chances of borrower strain and dampen credit growth.

NAB’s upcoming challenge is out in the open: the bank will publish its first-quarter trading update on Feb. 18. Investors will be watching closely for clues on loan growth, funding costs, and the trajectory of bad debts.

Shares of NAB climbed 2.07% on Wednesday, spearheading the local rally in bank stocks following the central bank’s unexpected shift in rate forecasts.

On the retail front, NAB and its counterparts have begun adjusting mortgage rates. Commonwealth Bank, Westpac, ANZ, and NAB are lifting variable home loan rates by 25 basis points, in line with the Reserve Bank of Australia’s recent hike. NAB’s new rates will kick in starting Feb. 13.

The RBA raised the cash rate target by 25 basis points—to 3.85%—on Tuesday, marking its first increase in two years. The central bank warned inflation is expected to remain above its target range for a while.

Governor Michele Bullock voiced caution about the outlook. “I don’t know if it’s in a (tightening) cycle,” she said, noting the board would be “actively monitoring” data, according to Reuters. Meanwhile, National Australia Bank chief economist Sally Auld remains convinced a rate hike will follow in May, with the balance of risks leaning toward further tightening. Reuters

Thursday saw a choppier mood in markets. Global tech stocks took another hit, weighing on risk appetite in Asia. Financials managed to hold their ground better than the rate-sensitive growth sectors.

Banks are zeroing in on margins. Net interest margin—the difference between earnings on loans and the cost of deposits—can expand if lending rates climb quicker than funding costs. But it can shrink too, especially if competition for deposits intensifies.

The downside scenario boils down to basics, not spreadsheets. If rising mortgage rates push arrears up, investors will shift their focus from loan pricing to provisioning and credit quality—particularly in portfolios loaded with housing loans.

The next key dates are coming up fast. On Feb. 17, investors will dissect the RBA’s February meeting minutes. Then, all eyes shift to NAB’s trading update on Feb. 18, searching for evidence that rising rates are lifting profits without pushing borrowers to the brink.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Guardant Health (GH) Stock Valuation Insights After 193% One-Year Gain
    June 28, 2026, 6:40 PM EDT. Guardant Health (GH) shares have surged 193.4% over the past year to around $149, raising questions about potential future gains. Despite strong price momentum, a Discounted Cash Flow (DCF) analysis estimates an intrinsic value near $159.10 per share, indicating the stock trades at a modest 6.2% discount. However, the company currently posts negative free cash flow ($232.49 million last twelve months) with projections to turn positive by 2030, reflecting ongoing challenges. Guardant Health scores just 1 out of 6 on valuation metrics, signaling caution for investors. The Price-to-Sales ratio is considered more relevant due to inconsistent profitability. Overall, GH appears fairly valued but market sentiment and fundamentals should be closely monitored for changes.

Latest articles

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

Kroger (NYSE:KR) chicken alert puts Private Selection label controls in focus

29 June 2026
Kroger (NYSE:KR) faces scrutiny after a USDA alert flagged mislabeled Private Selection Honey Dijon chicken in nine states, but with no confirmed adverse reactions and the product already off shelves, the stock closed Friday at $57.73, down 5 cents; any expansion of affected lots or confirmed cases could alter risk for investors.
Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held
Previous Story

Take-Two (TTWO) stock eyes a sharp open after forecast raise, GTA VI date held

Micron stock sinks nearly 10% as AI jitters hit chipmakers again
Next Story

Micron stock sinks nearly 10% as AI jitters hit chipmakers again

Go toTop